ReviewJournal of clinical medicine2019
History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.The Cochrane database of systematic reviews · 2020Pooled it
- MiRNA Polymorphisms and Hepatocellular Carcinoma Susceptibility: A Systematic Review and Network Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma and Combination Strategies.Maedica · 2026Review
- Radiation segmentectomy with resin microspheres for hepatocellular carcinoma: a state-of-the-art review highlighting evidence gaps and future research needs.EJNMMI physics · 2026Review
- Evaluation of end-to-end 3D absorbed dose distribution inEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Risk Stratification and Contemporary Predictors of Survival in Hepatocellular Carcinoma Treated With Transarterial Radioembolization.Gastroenterology research · 2025Article
- Phosphorus-32 microspheres: A dual-modality transarterial radioembolization approach for hepatocellular carcinoma therapy and Anti-PD1 immunotherapy potentiation.Materials today. Bio · 2025Article
- Sequential surgery following Yttrium-90 resin microspheres combined with targeted therapy and immunotherapy for primary hepatocellular carcinoma: a case report.Discover oncology · 2025Article
- SequentialAdvances in radiation oncology · 2025Article
- Cation Exchange Protocol to Radiolabel Rare-Earth Nanoparticles with Yttrium-90 for Radiotherapy and for Magnetic Resonance Imaging.ACS applied materials & interfaces · 2025Article
- Prognostic value of early response in predicting survival in hepatocellular carcinoma patients treated with selective internal radiation therapy.European radiology · 2025Article
- Advanced targeted microsphere embolization for arteriovenous malformations: state-of-the-art and future directions.Neuroradiology · 2025Review
- Advances and challenges in precision imaging.The Lancet. Oncology · 2025Review
- Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review.Hepatobiliary surgery and nutrition · 2024Review
- Tissue Ablation: Applications and Perspectives.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Selective internal radiation therapy segmentectomy: A new minimally invasive curative option for primary liver malignancies?World journal of gastroenterology · 2024Review
- Article
- Transarterial Radioembolization for Management of Hepatocellular Carcinoma.The oncologist · 2024Article
- Techniques to Optimize Radioembolization Tumor Coverage.Seminars in interventional radiology · 2024Review
- Arterial hypoperfusion as a negative predictive marker for primary hepatic malignancies treated with Y-90 glass microsphere transarterial radioembolization.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and affects millions worldwide. Due to the lack of effective systemic therapies for HCC, researchers have been investigating the use of locoregional tumor control with Yttrium-90 (Y90) radioembolization since the 1960s. Following the development of glass and resin Y90 microspheres in the early 1990s, Y90 radioembolization has been shown to be a safe and efficacious treatment for patients with HCC across Barcelona Clinic Liver Cancer (BCLC) stages. By demonstrating durable local control, good long term outcomes, and equivalent if not superior tumor responses and tolerability when compared to alternative therapies including transarterial chemoembolization (TACE) and sorafenib, Y90 radioembolization is being increasingly used in HCC treatment. More recently, investigations into variations in Y90 radioembolization technique including radiation segmentectomy and radiation lobectomy have further expanded its clinical utility. Here, we discuss the history and evolution of Y90 use in HCC. We outline key clinical trials that have established the safety and efficacy of Y90 radioembolization, and also summarize trials comparing its efficacy to existing HCC treatments. We conclude by reviewing the techniques of radiation segmentectomy and lobectomy, and by discussing dosimetry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.